Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
NCT ID: NCT00127283
Last Updated: 2017-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
829 participants
INTERVENTIONAL
2005-05-31
2007-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to evaluate the treatment of Recombinant Factor VIIa (eptacog alfa (activated)) in patients with acute intracerebral bleeding. It is expected that more patients will recover without severe permanent disability after acute treatment with Recombinant Factor VIIa by reducing further intracerebral bleeding.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
NCT00426803
Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding
NCT00184548
Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury
NCT00123591
Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage
NCT01566786
Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients
NCT01563523
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
eptacog alfa (activated)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pre-existing disability
* Haemophilia
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Registry (GCR, 1452)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novo Nordisk Investigational Site
Seattle, Washington, United States
Novo Nordisk Investigational Site
Madison, Wisconsin, United States
Novo Nordisk Investigational Site
Parkville, Victoria, Australia
Novo Nordisk Investigational Site
Camperdown, , Australia
Novo Nordisk Investigational Site
Birmingham, Alabama, United States
Novo Nordisk Investigational Site
Mobile, Alabama, United States
Novo Nordisk Investigational Site
Phoenix, Arizona, United States
Novo Nordisk Investigational Site
Fort Smith, Arkansas, United States
Novo Nordisk Investigational Site
Los Angeles, California, United States
Novo Nordisk Investigational Site
Oceanside, California, United States
Novo Nordisk Investigational Site
Orange, California, United States
Novo Nordisk Investigational Site
Sacramento, California, United States
Novo Nordisk Investigational Site
San Diego, California, United States
Novo Nordisk Investigational Site
San Francisco, California, United States
Novo Nordisk Investigational Site
San Francisco, California, United States
Novo Nordisk Investigational Site
Stanford, California, United States
Novo Nordisk Investigational Site
Denver, Colorado, United States
Novo Nordisk Investigational Site
Denver, Colorado, United States
Novo Nordisk Investigational Site
Englewood, Colorado, United States
Novo Nordisk Investigational Site
Hartford, Connecticut, United States
Novo Nordisk Investigational Site
Washington D.C., District of Columbia, United States
Novo Nordisk Investigational Site
Jacksonville, Florida, United States
Novo Nordisk Investigational Site
Melbourne, Florida, United States
Novo Nordisk Investigational Site
Tallahassee, Florida, United States
Novo Nordisk Investigational Site
Gosford, , Australia
Novo Nordisk Investigational Site
Tampa, Florida, United States
Novo Nordisk Investigational Site
Atlanta, Georgia, United States
Novo Nordisk Investigational Site
Augusta, Georgia, United States
Novo Nordisk Investigational Site
Decatur, Georgia, United States
Novo Nordisk Investigational Site
Honolulu, Hawaii, United States
Novo Nordisk Investigational Site
Chicago, Illinois, United States
Novo Nordisk Investigational Site
Chicago, Illinois, United States
Novo Nordisk Investigational Site
Maywood, Illinois, United States
Novo Nordisk Investigational Site
Peoria, Illinois, United States
Novo Nordisk Investigational Site
Fort Wayne, Indiana, United States
Novo Nordisk Investigational Site
Indianapolis, Indiana, United States
Novo Nordisk Investigational Site
Iowa City, Iowa, United States
Novo Nordisk Investigational Site
Lexington, Kentucky, United States
Novo Nordisk Investigational Site
Louisville, Kentucky, United States
Novo Nordisk Investigational Site
Baltimore, Maryland, United States
Novo Nordisk Investigational Site
Boston, Massachusetts, United States
Novo Nordisk Investigational Site
Boston, Massachusetts, United States
Novo Nordisk Investigational Site
Boston, Massachusetts, United States
Novo Nordisk Investigational Site
Detroit, Michigan, United States
Novo Nordisk Investigational Site
Golden Valley, Minnesota, United States
Novo Nordisk Investigational Site
Blackwater, Mississippi, United States
Novo Nordisk Investigational Site
Kansas City, Missouri, United States
Novo Nordisk Investigational Site
St Louis, Missouri, United States
Novo Nordisk Investigational Site
St Louis, Missouri, United States
Novo Nordisk Investigational Site
Las Vegas, Nevada, United States
Novo Nordisk Investigational Site
Lebanon, New Hampshire, United States
Novo Nordisk Investigational Site
Cherry Hill, New Jersey, United States
Novo Nordisk Investigational Site
Hackensack, New Jersey, United States
Novo Nordisk Investigational Site
Ridgewood, New Jersey, United States
Novo Nordisk Investigational Site
Buffalo, New York, United States
Novo Nordisk Investigational Site
New York, New York, United States
Novo Nordisk Investigational Site
Stony Brook, New York, United States
Novo Nordisk Investigational Site
Chapel Hill, North Carolina, United States
Novo Nordisk Investigational Site
Charlotte, North Carolina, United States
Novo Nordisk Investigational Site
Durham, North Carolina, United States
Novo Nordisk Investigational Site
Winston-Salem, North Carolina, United States
Novo Nordisk Investigational Site
Cincinnati, Ohio, United States
Novo Nordisk Investigational Site
Cleveland, Ohio, United States
Novo Nordisk Investigational Site
Portland, Oregon, United States
Novo Nordisk Investigational Site
Portland, Oregon, United States
Novo Nordisk Investigational Site
Allentown, Pennsylvania, United States
Novo Nordisk Investigational Site
Philadelphia, Pennsylvania, United States
Novo Nordisk Investigational Site
Philadelphia, Pennsylvania, United States
Novo Nordisk Investigational Site
Pittsburgh, Pennsylvania, United States
Novo Nordisk Investigational Site
Pittsburgh, Pennsylvania, United States
Novo Nordisk Investigational Site
Charleston, South Carolina, United States
Novo Nordisk Investigational Site
Chattanooga, Tennessee, United States
Novo Nordisk Investigational Site
Hashville, Tennessee, United States
Novo Nordisk Investigational Site
Memphis, Tennessee, United States
Novo Nordisk Investigational Site
Nashville, Tennessee, United States
Novo Nordisk Investigational Site
Dallas, Texas, United States
Novo Nordisk Investigational Site
Houston, Texas, United States
Novo Nordisk Investigational Site
San Antonio, Texas, United States
Novo Nordisk Investigational Site
Burlington, Vermont, United States
Novo Nordisk Investigational Site
Charlottesville, Virginia, United States
Novo Nordisk Investigational Site
Heidelberg Heights, , Australia
Novo Nordisk Investigational Site
Graz, , Austria
Novo Nordisk Investigational Site
Innsbruck, , Austria
Novo Nordisk Investigational Site
Antwerp, , Belgium
Novo Nordisk Investigational Site
Bruges, , Belgium
Novo Nordisk Investigational Site
Brussels, , Belgium
Novo Nordisk Investigational Site
Brussels, , Belgium
Novo Nordisk Investigational Site
Sao Cristóvao, , Brazil
Novo Nordisk Investigational Site
Vila Clementino, , Brazil
Novo Nordisk Investigational Site
Edmonton, Alberta, Canada
Novo Nordisk Investigational Site
Halifax, Nova Scotia, Canada
Novo Nordisk Investigational Site
Calgary, , Canada
Novo Nordisk Investigational Site
Greenfield Park, , Canada
Novo Nordisk Investigational Site
London, , Canada
Novo Nordisk Investigational Site
Mississauga, , Canada
Novo Nordisk Investigational Site
Montreal, , Canada
Novo Nordisk Investigational Site
Montreal, , Canada
Novo Nordisk Investigational Site
Ottawa, , Canada
Novo Nordisk Investigational Site
Québec, , Canada
Novo Nordisk Investigational Site
Saint John, , Canada
Novo Nordisk Investigational Site
Saskatoon, , Canada
Novo Nordisk Investigational Site
Thunder Bay, , Canada
Novo Nordisk Investigational Site
Toronto, , Canada
Novo Nordisk Investigational Site
Vancouver, , Canada
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Novo Nordisk Investigational Site
Zagreb, , Croatia
Novo Nordisk Investigational Site
Aalborg, , Denmark
Novo Nordisk Investigational Site
Aarhus, , Denmark
Novo Nordisk Investigational Site
Copenhagen, , Denmark
Novo Nordisk Investigational Site
Glostrup Municipality, , Denmark
Novo Nordisk Investigational Site
Helsinki, , Finland
Novo Nordisk Investigational Site
Kuopio, , Finland
Novo Nordisk Investigational Site
Seinäjoki, , Finland
Novo Nordisk Investigational Site
Turku, , Finland
Novo Nordisk Investigational Site
Bordeaux, , France
Novo Nordisk Investigational Site
Paris, , France
Novo Nordisk Investigational Site
Paris, , France
Novo Nordisk Investigational Site
Paris, , France
Novo Nordisk Investigational Site
Toulouse, , France
Novo Nordisk Investigational Site
Berlin, , Germany
Novo Nordisk Investigational Site
Dresden, , Germany
Novo Nordisk Investigational Site
Essen, , Germany
Novo Nordisk Investigational Site
Heidelberg, , Germany
Novo Nordisk Investigational Site
Leipzig, , Germany
Novo Nordisk Investigational Site
Mannheim, , Germany
Novo Nordisk Investigational Site
Minden, , Germany
Novo Nordisk Investigational Site
München, , Germany
Novo Nordisk Investigational Site
Münster, , Germany
Novo Nordisk Investigational Site
Hong Kong, , Hong Kong
Novo Nordisk Investigational Site
Tel Aviv, , Israel
Novo Nordisk Investigational Site
Tel Litwinsky, , Israel
Novo Nordisk Investigational Site
Florence, , Italy
Novo Nordisk Investigational Site
Pavia, , Italy
Novo Nordisk Investigational Site
Perugia, , Italy
Novo Nordisk Investigational Site
Roma, , Italy
Novo Nordisk Investigational Site
Amsterdam, , Netherlands
Novo Nordisk Investigational Site
Amsterdam, , Netherlands
Novo Nordisk Investigational Site
Eindhoven, , Netherlands
Novo Nordisk Investigational Site
Heerlen, , Netherlands
Novo Nordisk Investigational Site
Rotterdam, , Netherlands
Novo Nordisk Investigational Site
Utrecht, , Netherlands
Novo Nordisk Investigational Site
Bergen, , Norway
Novo Nordisk Investigational Site
Kristiansand, , Norway
Novo Nordisk Investigational Site
Nordbyhagen, , Norway
Novo Nordisk Investigational Site
Stavanger, , Norway
Novo Nordisk Investigational Site
Trondheim, , Norway
Novo Nordisk Investigational Site
Singapore, , Singapore
Novo Nordisk Investigational Site
Singapore, , Singapore
Novo Nordisk Investigational Site
Badalona, , Spain
Novo Nordisk Investigational Site
Barcelona, , Spain
Novo Nordisk Investigational Site
Barcelona, , Spain
Novo Nordisk Investigational Site
Girona, , Spain
Novo Nordisk Investigational Site
Madrid, , Spain
Novo Nordisk Investigational Site
Linköping, , Sweden
Novo Nordisk Investigational Site
Malmo, , Sweden
Novo Nordisk Investigational Site
Stockholm, , Sweden
Novo Nordisk Investigational Site
Stockholm, , Sweden
Novo Nordisk Investigational Site
Stockholm, , Sweden
Novo Nordisk Investigational Site
Umeå, , Sweden
Novo Nordisk Investigational Site
Lausanne, , Switzerland
Novo Nordisk Investigational Site
Taipei, , Taiwan
Novo Nordisk Investigational Site
Taipei, , Taiwan
Novo Nordisk Investigational Site
Taoyuan District, , Taiwan
Novo Nordisk Investigational Site
Bangkok, , Thailand
Novo Nordisk Investigational Site
Bangkok, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hsia CC, Chin-Yee IH, McAlister VC. Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. Ann Surg. 2008 Jul;248(1):61-8. doi: 10.1097/SLA.0b013e318176c4ec.
Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T; FAST Trial Investigators. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008 May 15;358(20):2127-37. doi: 10.1056/NEJMoa0707534.
Eilertsen H, Menon CS, Law ZK, Chen C, Bath PM, Steiner T, Desborough MJ, Sandset EC, Sprigg N, Al-Shahi Salman R. Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage. Cochrane Database Syst Rev. 2023 Oct 23;10(10):CD005951. doi: 10.1002/14651858.CD005951.pub5.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Trials at Novo Nordisk
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2004-004202-24
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
F7ICH-1641
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.